The ROCKstar study: belumosudil for chronic GvHD

Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the top-line results from the ongoing Phase II ROCKstar study (NCT03640481), investigating belumosudil for chronic graft-versus-host disease (cGvHD) after two or more prior lines of therapy. The study has found that treatment with belumosudil resulted in high overall response rates (ORR) which were durable and clinically meaningful. Additionally, belumosudil was well-tolerated, with limited and manageable adverse events. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.